James Mackin - CryoLife Chairman
Chairman
Mr. James Patrick Mackin Chairman of the Board, President, Chief Executive Officer of the Company. He has more than 20 years of experience in the medical device industry. Prior to joining CryoLife, Mr. Mackin served as President of Cardiac Rhythm Disease Management, the largest operating division of Medtronic, Inc. At Medtronic, he previously held the positions of Vice President, Vascular, Western Europe and Vice President and General Manager, Endovascular Business Unit. Prior to joining Medtronic in 2002, Mr. Mackin worked for six years at Genzyme, Inc. serving as Senior Vice President and General Manager for the Cardiovascular Surgery Business Unit and as Director of Sales, Surgical Products division. Before joining Genzyme, Mr. Mackin spent four years at DeknatelSnowdenPencer, Inc. in various roles and three years as a First Lieutenant in the U.S. Army since 2015.
| Age | 53 |
| Tenure | 9 years |
| Professional Marks | MBA |
| Phone | 770 426-0031 |
| Web | www.Artivion.com |
James Mackin Latest Insider Activity
Tracking and analyzing the buying and selling activities of James Mackin against CryoLife stock is an integral part of due diligence when investing in CryoLife. James Mackin insider activity provides valuable insight into whether CryoLife is net buyers or sellers over its current business cycle. Note, CryoLife insiders must abide by specific rules, including filing SEC forms every time they buy or sell CryoLife'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
James Mackin over two months ago Disposition of 59225 shares by James Mackin of Artivion at 16.3 subject to Rule 16b-3 |
CryoLife Management Efficiency
The company has Return on Asset of 1.01 % which means that on every $100 spent on assets, it made $1.01 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.57 %, implying that it generated $0.57 on every 100 dollars invested. CryoLife's management efficiency ratios could be used to measure how well CryoLife manages its routine affairs as well as how well it operates its assets and liabilities.The company has 363.37 M in debt with debt to equity (D/E) ratio of 1.17, which is OK given its current industry classification. CryoLife has a current ratio of 4.13, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist CryoLife until it has trouble settling it off, either with new capital or with free cash flow. So, CryoLife's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like CryoLife sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for CryoLife to invest in growth at high rates of return. When we think about CryoLife's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 10 records | CHAIRMAN Age | ||
| Gary Bagley | HE Equipment Services | 71 | |
| Randall Hogan | Pentair PLC | 60 | |
| David Jones | Pentair PLC | 71 | |
| Herbert Henkel | Herc Holdings | 70 | |
| Patrick Campbell | Herc Holdings | 68 | |
| William Franke | Wizz Air Holdings | 79 | |
| Linda Levinson | Herc Holdings | 73 | |
| Ronald Nelson | Avis Budget Group | 64 | |
| Shuang Chen | China Aircraft Leasing | 48 | |
| Edward Shoen | U Haul Holding | 68 | |
Management Performance
| Return On Equity | 0.57 | |||
| Return On Asset | 1.01 |
CryoLife Leadership Team
Elected by the shareholders, the CryoLife's board of directors comprises two types of representatives: CryoLife inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CryoLife. The board's role is to monitor CryoLife's management team and ensure that shareholders' interests are well served. CryoLife's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CryoLife's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Bevevino, Independent Director | ||
| Ashley Lee, CFO, COO, Executive Vice President | ||
| Thomas Bogenschutz, Senior Vice President - EMEA, General Manager - Hechingen | ||
| Jeffrey Burbank, Independent Director | ||
| Jon Salveson, Independent Director | ||
| Jean Holloway, Senior Vice President, Chief Compliance Officer, General Counsel, Secretary | ||
| David Gale, Vice President - Research & Development | ||
| Thomas Ackerman, Independent Director | ||
| Harvey Morgan, Independent Director | ||
| James Benson, Independent Director | ||
| James McDermid, Chief Human Resource Officer | ||
| William Matthews, Senior Vice President - Operations, Quality, and Regulatory | ||
| Ronald Elkins, Independent Director | ||
| Scott Capps, Vice President - Clinical Research | ||
| Marna Borgstrom, Independent Director | ||
| James Bullock, Independent Director | ||
| Matthew Getz, Vice President - Human Resources | ||
| D Lee, Chief Financial Officer, Chief Operating Officer, Executive Vice President | ||
| James Mackin, Chairman of the Board, President, Chief Executive Officer, Director | ||
| Anthony Semedo, Independent Director | ||
| Dennis Maier, Vice President - Operations | ||
| Ronald McCall, Presiding Independent Director | ||
| Dan Bevevino, Independent Director | ||
| David Lang, Senior Vice President - International Sales and Marketing | ||
| F Barthold, Vice President - Research and Development | ||
| Greg Chodaczek, IR Contact Officer | ||
| Amy Horton, Chief Accounting Officer, Vice President | ||
| Michael Simpson, Senior Vice President - Regulatory Affairs and Quality Assurance | ||
| John Davis, Senior Vice President - Global Sales and Marketing |
CryoLife Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CryoLife a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.57 | |||
| Return On Asset | 1.01 | |||
| Profit Margin | 0.63 % | |||
| Operating Margin | 12.82 % | |||
| Current Valuation | 1.07 B | |||
| Shares Outstanding | 39.33 M | |||
| Shares Owned By Insiders | 3.70 % | |||
| Shares Owned By Institutions | 83.78 % | |||
| Number Of Shares Shorted | 3.47 M | |||
| Price To Earning | 425.71 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards CryoLife in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, CryoLife's short interest history, or implied volatility extrapolated from CryoLife options trading.
Pair Trading with CryoLife
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CryoLife position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CryoLife will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Hershey could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Hershey when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Hershey - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Hershey Co to buy it.
The correlation of Hershey is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Hershey moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Hershey moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Hershey can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in CryoLife Stock
If you are still planning to invest in CryoLife check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CryoLife's history and understand the potential risks before investing.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |